Mesa Laboratories (NASDAQ:MLAB) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Technical move: Mesa Laboratories' shares crossed above their 200‑day moving average ($84.01), trading as high as $101.98 and last at $95.76 on volume of 147,545.
• Mixed analyst sentiment with a negative consensus: While some firms upgraded the stock (e.g., Wall Street Zen to "strong‑buy" and Wells Fargo raised its price objective), MarketBeat shows a consensus rating of "Reduce" with a consensus target price of $94.00.
• Fundamentals and insider activity: The company beat quarterly estimates with $3.07 EPS (vs. $2.41 expected) and $65.13M revenue, announced a $0.16 quarterly dividend (0.7% yield), and insiders bought shares recently (6,116 shares valued at ~$452k over 90 days).

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $84.01 and traded as high as $101.98. Mesa Laboratories shares last traded at $95.76, with a volume of 147,545 shares.

Analyst Upgrades and Downgrades

MLAB has been the topic of a number of research analyst reports. Weiss Ratings reissued a "sell (d)" rating on shares of Mesa Laboratories in a report on Thursday, January 22nd. Wall Street Zen raised shares of Mesa Laboratories from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 7th. Wells Fargo & Company raised their price objective on shares of Mesa Laboratories from $83.00 to $94.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 4th. Finally, Zacks Research raised shares of Mesa Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, January 9th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $94.00.

Mesa Laboratories Trading Down 3.7%

The business's fifty day simple moving average is $90.70 and its two-hundred day simple moving average is $84.01. The company has a market cap of $529.07 million, a price-to-earnings ratio of 149.63 and a beta of 0.90. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 EPS for the quarter, beating analysts' consensus estimates of $2.41 by $0.66. The business had revenue of $65.13 million for the quarter, compared to analysts' expectations of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. On average, equities analysts predict that Mesa Laboratories, Inc. will post 7.26 EPS for the current year.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Friday, May 29th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 29th. Mesa Laboratories's payout ratio is presently 100.00%.

Insider Activity

In other Mesa Laboratories news, Director Shiraz Shabanali Ladiwala bought 3,500 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $72.23 per share, with a total value of $252,805.00. Following the acquisition, the director directly owned 8,523 shares of the company's stock, valued at $615,616.29. The trade was a 69.68% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark Christopher Capone bought 1,301 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $76.35 per share, for a total transaction of $99,331.35. Following the completion of the acquisition, the director directly owned 3,429 shares in the company, valued at approximately $261,804.15. This trade represents a 61.14% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 6,116 shares of company stock valued at $452,076 in the last ninety days. 4.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mesa Laboratories

A number of institutional investors have recently modified their holdings of MLAB. Simcoe Capital Management LLC acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $12,794,000. Boston Partners grew its position in Mesa Laboratories by 2,009.5% in the 3rd quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier's stock valued at $7,664,000 after buying an additional 108,936 shares during the last quarter. Diamond Hill Capital Management Inc. grew its position in Mesa Laboratories by 218.0% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 123,381 shares of the medical instruments supplier's stock valued at $8,268,000 after buying an additional 84,582 shares during the last quarter. Roubaix Capital LLC purchased a new position in Mesa Laboratories in the 3rd quarter valued at $5,137,000. Finally, Millennium Management LLC grew its position in Mesa Laboratories by 131.9% in the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier's stock valued at $8,967,000 after buying an additional 76,107 shares during the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.